跳至主要内容
临床试验/JPRN-UMIN000011651
JPRN-UMIN000011651招募中未知

Evaluation for the effectiveness and safety for Autologous Bone Marrow Cell infusion (ABMi) therapy for HCV infected liver cirrhosis patient. - ABMi therapy for liver cirrhosis (HCV)

Yamaguchi University Graduate School of Medicine0 个研究点目标入组 34 人开始时间: 2013年9月14日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
34

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1) Liver cirrhosis induced by other factor without HCV infection and unknown reasons (2) have a malignant neoplasm, or a history of malignant neoplasm (Including HCC) (3) have risk of Esophageal or/and gastric varices (4) Renal dysfunction with 2mg/dL or higher serum creatinine (5) hemoglobin under 8g/dL or Platelets under 50/mL or Prothrombin activity under 40% (6) Total bilirubin 3.0mg/dL or more (7) Performance Status 3 or 4 (8) Cases that cannot obtain the informed consent to autologous blood transfusion (9) undeniable possibility for HBV infection, HIV infection, ATL infection, human parvovirus B19 infection (10) Pregnancy (11) not fit for general anesthesia (12) have a severe allergic reaction to contrast dye or a history of a severe allergic reaction to contrast dye (13) other conditions that doctor considered not suitable for the study

研究者

发起方
Yamaguchi University Graduate School of Medicine

相似试验